A retrospective observational study showed similar 90-day survival for initial treatment of invasive aspergillosis. The study recommends twice considering the use of antifungal triazoles instead of liposomal amphotericin B (L-AmB). L-AmB may be an appropriate initial choice for a severe fungal infection. Triazoles include drugs such as voriconazole that are commonly used in the treatment. The study suggests more than one initial treatment option. Invasive aspergillosis is a serious, life-threatening fungal infection. Study results support flexibility in initiation therapy.